论文部分内容阅读
目的:评价琥珀酸亚铁配合抗幽门螺杆菌药物联用对缺铁性贫血伴幽门螺杆菌感染患者的临床疗效。方法:选取2015年10月—2016年10月间收治的缺铁性贫血(IDA)伴幽门螺杆菌感染患者100例,采用随机分组法将其分为治疗组和对照组,每组50例;对照组患者给予琥珀酸亚铁和维生素C治疗,治疗组患者在对照组基础上加用抗幽门螺杆菌药物(奥美拉唑、阿莫西林和左氧氟沙星)治疗,评价两组患者治疗前后的贫血各指标测得值变化情况。结果:治疗后两组患者血小板、总铁结合力都有所下降,而红细胞平均体积、血清铁和转铁蛋白测得值上升,与治疗前比较其差异有统计学意义(P<0.05);治疗组患者治疗后的各项指标变化幅度明显高于对照组;治疗组治疗后的幽门螺杆菌清除率和总有效率分别为91.00%和96.00%高于对照组为4.00%和78.00%(P<0.05)。结论:在缺铁性贫血伴幽门螺杆菌感染患者的治疗中,采用琥珀酸亚铁配合抗幽门螺杆菌药物治疗的疗效优于单用琥珀酸亚铁。
OBJECTIVE: To evaluate the clinical efficacy of ferrous succinate in combination with anti-Helicobacter pylori infection in patients with iron-deficiency anemia and Helicobacter pylori infection. Methods: One hundred patients with IDA with Helicobacter pylori infection were selected from October 2015 to October 2016. The patients were divided into treatment group and control group with 50 cases in each group. Patients in the control group were treated with ferrous succinate and vitamin C. The patients in the treatment group were treated with anti-Helicobacter pylori drugs (omeprazole, amoxicillin and levofloxacin) on the basis of the control group, and the anemia in both groups before and after treatment was evaluated Changes in the measured value of each indicator. Results: After treatment, the platelet and total iron - binding capacity decreased in both groups, while the average volume of erythrocytes, serum iron and transferrin increased, with statistical significance (P <0.05). After treatment, the changes of various indexes in the treatment group were significantly higher than those in the control group. The H. pylori clearance rate and total effective rate in the treatment group were 91.00% and 96.00%, respectively, higher than that in the control group (4.00% and 78.00%, P <0.05). CONCLUSION: In the treatment of patients with iron-deficiency anemia and Helicobacter pylori infection, the efficacy of using ferrous succinate in combination with anti-Helicobacter pylori therapy is better than that of ferrous succinate alone.